PMID- 23760780
OWN - NLM
STAT- MEDLINE
DCOM- 20140131
LR  - 20211203
IS  - 1179-2019 (Electronic)
IS  - 1174-5878 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Dec
TI  - Optimal management of Ewing sarcoma family of tumors: recent developments in 
      systemic therapy.
PG  - 473-92
LID - 10.1007/s40272-013-0037-1 [doi]
AB  - The Ewing sarcoma family of tumors (ESFT) is defined by cell surface expression 
      of CD99 and a translocation involving EWS and an ETS partner. Cytotoxic 
      chemotherapy remains the benchmark of first- and second-line therapy, and 
      although the majority of patients with localized disease are cured, almost one 
      third of patients relapse or progress from their disease. Moreover, cure remains 
      elusive in most patients who present with distant metastases. In recent years, 
      the ESFT literature has been dominated by reports of attempts at modulating the 
      insulin-like growth factor (IGF) receptor (IGFR). Unfortunately, three phase II 
      studies examining inhibiting antibodies to IGFR-1 published disappointing 
      results. Whether these results were due to failure to modulate the pathway or 
      other limitations in study design and/or patient selection remain unclear. Other 
      novel strategies currently being investigated in ESFT include tyrosine kinase, 
      mammalian target of rapamycin (mTOR), and poly(ADP-ribose) polymerase (PARP) 
      inhibitors.
FAU - Owens, Cormac
AU  - Owens C
AD  - The Division of Hematology/Oncology, Department of Pediatrics, Hospital for Sick 
      Children, University of Toronto, Toronto, ON, M5G 1N6, Canada, 
      cormacowens@yahoo.com.
FAU - Abbott, Lesleigh S
AU  - Abbott LS
FAU - Gupta, Abha A
AU  - Gupta AA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Paediatr Drugs
JT  - Paediatric drugs
JID - 100883685
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Bone Neoplasms/*drug therapy/genetics/surgery
MH  - Chemotherapy, Adjuvant
MH  - Humans
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Metabolic Networks and Pathways
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Poly(ADP-ribose) Polymerase Inhibitors
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Sarcoma, Ewing/*drug therapy/genetics/surgery
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
MH  - Translocation, Genetic
EDAT- 2013/06/14 06:00
MHDA- 2014/02/01 06:00
CRDT- 2013/06/14 06:00
PHST- 2013/06/14 06:00 [entrez]
PHST- 2013/06/14 06:00 [pubmed]
PHST- 2014/02/01 06:00 [medline]
AID - 10.1007/s40272-013-0037-1 [doi]
PST - ppublish
SO  - Paediatr Drugs. 2013 Dec;15(6):473-92. doi: 10.1007/s40272-013-0037-1.